243 related articles for article (PubMed ID: 26635203)
21. Complex patterns of chromosome 9 alterations including the p16INK4a locus in Wilms tumours.
Natrajan R; Warren W; Messahel B; Reis-Filho JS; Brundler MA; Dome JS; Grundy PE; Vujanic G; Pritchard-Jones K; Jones C
J Clin Pathol; 2008 Jan; 61(1):95-102. PubMed ID: 17369505
[TBL] [Abstract][Full Text] [Related]
22. Changes in WT1 splicing are associated with a specific gene expression profile in Wilms' tumour.
Baudry D; Faussillon M; Cabanis MO; Rigolet M; Zucker JM; Patte C; Sarnacki S; Boccon-Gibod L; Junien C; Jeanpierre C
Oncogene; 2002 Aug; 21(36):5566-73. PubMed ID: 12165855
[TBL] [Abstract][Full Text] [Related]
23. The Iroquois homeobox proteins IRX3 and IRX5 have distinct roles in Wilms tumour development and human nephrogenesis.
Holmquist Mengelbier L; Lindell-Munther S; Yasui H; Jansson C; Esfandyari J; Karlsson J; Lau K; Hui CC; Bexell D; Hopyan S; Gisselsson D
J Pathol; 2019 Jan; 247(1):86-98. PubMed ID: 30246301
[TBL] [Abstract][Full Text] [Related]
24. Regulation of insulin-like growth factor I receptor gene expression by the Wilms' tumor suppressor WT1.
Werner H; Roberts CT; Rauscher FJ; LeRoith D
J Mol Neurosci; 1996; 7(2):111-23. PubMed ID: 8873895
[TBL] [Abstract][Full Text] [Related]
25. Identification of WTAP, a novel Wilms' tumour 1-associating protein.
Little NA; Hastie ND; Davies RC
Hum Mol Genet; 2000 Sep; 9(15):2231-9. PubMed ID: 11001926
[TBL] [Abstract][Full Text] [Related]
26. CITED1 confers stemness to Wilms tumor and enhances tumorigenic responses when enriched in the nucleus.
Murphy AJ; Pierce J; de Caestecker C; Ayers GD; Zhao A; Krebs JR; Saito-Diaz VK; Lee E; Perantoni AO; de Caestecker MP; Lovvorn HN
Oncotarget; 2014 Jan; 5(2):386-402. PubMed ID: 24481423
[TBL] [Abstract][Full Text] [Related]
27. Frequent association of beta-catenin and WT1 mutations in Wilms tumors.
Maiti S; Alam R; Amos CI; Huff V
Cancer Res; 2000 Nov; 60(22):6288-92. PubMed ID: 11103785
[TBL] [Abstract][Full Text] [Related]
28. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.
Gadd S; Huff V; Huang CC; Ruteshouser EC; Dome JS; Grundy PE; Breslow N; Jennings L; Green DM; Beckwith JB; Perlman EJ
Neoplasia; 2012 Aug; 14(8):742-56. PubMed ID: 22952427
[TBL] [Abstract][Full Text] [Related]
29. Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms' tumour and colorectal cancer.
Wagner KJ; Cooper WN; Grundy RG; Caldwell G; Jones C; Wadey RB; Morton D; Schofield PN; Reik W; Latif F; Maher ER
Oncogene; 2002 Oct; 21(47):7277-82. PubMed ID: 12370819
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of epithelial development and neoplasia in the metanephric kidney.
Davies JA; Perera AD; Walker CL
Int J Dev Biol; 1999; 43(5):473-8. PubMed ID: 10535327
[TBL] [Abstract][Full Text] [Related]
31. A Murine Model of K-RAS and β-Catenin Induced Renal Tumors Expresses High Levels of E2F1 and Resembles Human Wilms Tumor.
Yi Y; Polosukhina D; Love HD; Hembd A; Pickup M; Moses HL; Lovvorn HN; Zent R; Clark PE
J Urol; 2015 Dec; 194(6):1762-70. PubMed ID: 25934441
[TBL] [Abstract][Full Text] [Related]
32. Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors.
Vuononvirta R; Sebire NJ; Dallosso AR; Reis-Filho JS; Williams RD; Mackay A; Fenwick K; Grigoriadis A; Ashworth A; Pritchard-Jones K; Brown KW; Vujanic GM; Jones C
Clin Cancer Res; 2008 Dec; 14(23):7635-44. PubMed ID: 19047088
[TBL] [Abstract][Full Text] [Related]
33. Splicing of exon 5 in the WT1 gene is disrupted in Wilms' tumour.
Simms LA; Algar EM; Smith PJ
Eur J Cancer; 1995 Dec; 31A(13-14):2270-6. PubMed ID: 8652255
[TBL] [Abstract][Full Text] [Related]
34. Expression of hepatocyte growth factor and its receptor met in Wilms' tumors and nephrogenic rests reflects their roles in kidney development.
Vuononvirta R; Sebire NJ; Messahel B; Perusinghe N; Reis-Filho JS; Pritchard-Jones K; Vujanic GM; Jones C
Clin Cancer Res; 2009 Apr; 15(8):2723-30. PubMed ID: 19318497
[TBL] [Abstract][Full Text] [Related]
35. Molecular and cellular biology of Wilms' tumour.
Maitland NJ; Brown KW; Poirier V; Shaw AP; Williams J
Anticancer Res; 1989; 9(5):1417-26. PubMed ID: 2556071
[TBL] [Abstract][Full Text] [Related]
36. Canonical WNT signalling determines lineage specificity in Wilms tumour.
Fukuzawa R; Anaka MR; Weeks RJ; Morison IM; Reeve AE
Oncogene; 2009 Feb; 28(8):1063-75. PubMed ID: 19137020
[TBL] [Abstract][Full Text] [Related]
37. Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor.
Woods AD; Berlow NE; Ortiz MV; Dela Cruz F; Siddiquee A; Coutinho DF; Purohit R; Freier KET; Michalek JE; Lathara M; Matlock K; Srivivasa G; Royer-Pokora B; Veselska R; Kung AL; Keller C
Pediatr Blood Cancer; 2022 Feb; 69(2):e29401. PubMed ID: 34693628
[TBL] [Abstract][Full Text] [Related]
38. Immunoexpression of SALL4 in Wilms tumors and developing kidney.
Deisch J; Raisanen J; Rakheja D
Pathol Oncol Res; 2011 Sep; 17(3):639-44. PubMed ID: 21258884
[TBL] [Abstract][Full Text] [Related]
39. Impaired cell fate through gain-of-function mutations in a chromatin reader.
Wan L; Chong S; Xuan F; Liang A; Cui X; Gates L; Carroll TS; Li Y; Feng L; Chen G; Wang SP; Ortiz MV; Daley SK; Wang X; Xuan H; Kentsis A; Muir TW; Roeder RG; Li H; Li W; Tjian R; Wen H; Allis CD
Nature; 2020 Jan; 577(7788):121-126. PubMed ID: 31853060
[TBL] [Abstract][Full Text] [Related]
40. Exclusion of the Wilms tumour gene (WT1) promoter as a site of frequent mutation in Wilms tumour.
Grubb GR; Yun K; Reeve AE; Eccles MR
Oncogene; 1995 Apr; 10(8):1677-81. PubMed ID: 7731725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
